|
1.
|
|
11 p, 6.9 MB |
NOX2 control over energy metabolism plays a role in acute myeloid leukaemia prognosis and survival
/
Ijurko, Carla (Instituto de Investigación Biomédica de Salamanca) ;
Romo-González, Marta (Instituto de Investigación Biomédica de Salamanca) ;
García-Calvo, Clara (Instituto de Investigación Biomédica de Salamanca) ;
Sardina, José Luis (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sánchez-Bernal, Carmen (Instituto de Investigación Biomédica de Salamanca) ;
Sánchez-Yagüe, Jesús (Instituto de Investigación Biomédica de Salamanca) ;
Elena-Herrmann, Bénédicte (University Grenoble Alpes) ;
Villaret, Joran (University Grenoble Alpes) ;
Garrel, Catherine (Department of Biochemistry. Hospital of Grenoble Alpes) ;
Mondet, Julie (Department of Molecular Pathology. Hospital of Grenoble Alpes) ;
Mossuz, Pascal (Department of Biological Hematology. Hospital of Grenoble Alpes) ;
Hernández-Hernández, Ángel (Instituto de Investigación Biomédica de Salamanca) ;
Universitat Autònoma de Barcelona
Acute myeloid leukaemia (AML) is a highly heterogeneous disease, however the therapeutic approaches have hardly changed in the last decades. Metabolism rewiring and the enhanced production of reactive oxygen species (ROS) are hallmarks of cancer. [...]
2023 -  10.1016/j.freeradbiomed.2023.10.013
Free Radical Biology and Medicine, Vol. 209 (20 2023) , p. 18-28
|
|
|
2.
|
|
5 p, 548.5 KB |
HTLV-1 infection in solid organ transplant donors and recipients in Spain
/
De Mendoza, Carmen (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Roc, Lourdes (Hospital Universitario Miguel Servet (Saragossa)) ;
Benito, Rafael (Hospital Clínico Universitario Lozano Blesa) ;
Reina, Gabriel (Clínica Universidad de Navarra) ;
Ramos, Jose Manuel (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Gómez, Cesar (Complejo Hospitalario de Toledo) ;
Aguilera, Antonio ((Hospital Conxo-CHUS (Santiago)) ;
Rodríguez-Iglesias, Manuel Antonio (Hospital Universitario de Puerto Real (Cadis, Andalusia)) ;
García-Costa, Juan (Complejo Hospitalario Universitario de Ourense) ;
Fernández-Alonso, Miriam (Clínica Universidad de Navarra) ;
Soriano, Vicente (UNIR Health Sciences School & Medical Centre (Madrid)) ;
Rodríguez, Carmen (Centro Sanitario Sandoval) ;
Vera, Mar (Centro Sanitario Sandoval) ;
Del Romero, Jorge (Centro Sanitario Sandoval) ;
Marcaida, Goitzane (Hospital General Universitario de Valencia) ;
Ocete, María Dolores (Hospital General Universitario de Valencia) ;
Caballero Requero, Estrella (Hospital Universitari Vall d'Hebron) ;
Molina Romero, Israel (Hospital Universitari Vall d'Hebron) ;
Rodríguez-Calviño, Juan J. (Hospital Conxo-CHUS (Santiago)) ;
Navarro, Daniel (Hospital Conxo-CHUS (Santiago)) ;
Rivero, Constanza (Hospital Conxo-CHUS (Santiago)) ;
Vilariño, M.D. (Hospital Conxo-CHUS (Santiago)) ;
Benito, Rafael (Hospital Clínico Universitario Lozano Blesa (Saragossa)) ;
Algarate, S. (Hospital Clínico Universitario Lozano Blesa (Saragossa)) ;
Gil, Joaquina (Hospital Clínico Universitario Lozano Blesa (Saragossa)) ;
Ortiz de Lejarazu, Raúl (Hospital Clínico Universitario de Valladolid) ;
Rojo, Silvia (Hospital Clínico Universitario de Valladolid) ;
Eirós, José M. ;
San Miguel, A. ;
Manzardo, Christian ;
Miró, José M ;
García, Juan ;
Paz, Irmia ;
Poveda, Eva ;
Calderón, Enrique J. ;
Escudero, Domingo ;
Trigo-Daporta, Matilde ;
Diz, Julio ;
García-Campello, Marta ;
Rodríguez Iglesias, Manuel ;
Hernández Betancor, Araceli Pascual ;
Martín, Antonio Manuel ;
Ramos, José Manuel ;
Gimeno Gascon, Adelina ;
Gutiérrez, Félix ;
Rodríguez, Juan Carlos ;
Sánchez, V. ;
Gómez Hernando, Cesar ;
Cilla, Gustavo ;
Pérez-Trallero, Emilio ;
López Aldeguer, Jose ;
Fernández Pereira, Luis ;
Niubó, Jordi ;
Hernández, M. ;
López Lirola, Ana María ;
Gómez Sirvent, Juan Luis ;
Force, Lluís L. ;
Cifuentes, Carmen ;
Pérez-Castro, Sonia ;
Morano, Luís Enrique ;
Raya, Carmen ;
González Praetorius, Alejandro ;
Pérez, Jose Luis ;
Peñaranda Vera, Maria (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Hernáez Crespo, Silvia (Hospital Universitario de Basurto (Bilbao)) ;
Montejo, Jose Miguel (Hospital de Cruces (Barakaldo, Biscaia)) ;
Roc, Lourdes (Hospital Universitario Miguel Servet (Saragossa)) ;
Martínez Sapiña, Ana (Hospital Universitario Miguel Servet (Saragossa)) ;
Viciana, Isabel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Cabezas, Teresa (Hospital de Poniente (Almería)) ;
Lozano, Ana Belén (Hospital de Poniente (Almería)) ;
Fernández, J.M. (Hospital de Poniente (Almería)) ;
García-Bermejo, Isabel (Hospital Universitario de Getafe) ;
Gaspar Alonso-Vega, Gabriel (Hospital Universitario de Getafe) ;
García, R. (Hospital Universitario Fundación Jiménez Díaz) ;
Górgolas Hernandez-Mora, Miguel (Hospital Universitario Fundación Jiménez Díaz) ;
Vegas, C. (Hospital Universitario Fundación Jiménez Díaz) ;
Blas, J. (Hospital Universitario Fundación Jiménez Díaz) ;
Miralles, Pilar (Hospital Gregorio Marañón (Madrid)) ;
Valeiro, M. (Hospital Gregorio Marañón (Madrid)) ;
Aldamiz, T. (Hospital Gregorio Marañón (Madrid)) ;
Margall, Núria (Institut d'Investigació Biomèdica Sant Pau) ;
Guardia, C. (ICS (Barcelona)) ;
Do Pico, E. (ICS (Barcelona)) ;
Polo, I. (Complejo Hospitalario de Navarra (Pamplona)) ;
Aguinaga, A. (Complejo Hospitalario de Navarra (Pamplona)) ;
Ezpeleta, C. (Complejo Hospitalario de Navarra (Pamplona)) ;
Sauleda, Silvia (Banco de Sangre & Tejidos (Barcelona)) ;
Piron, Maria (Banco de Sangre & Tejidos (Barcelona)) ;
González, R. (Centro de Transfusiones (Madrid)) ;
Barea, L. 4u Centro de Transfusiones (Madrid) ;
Jiménez, A. (Centro de Hemoterapia y Hemodonación de Castilla y León (Valladolid)) ;
Blanco, L. (Centro de Hemoterapia y Hemodonación de Castilla y León (Valladolid)) ;
Suárez, A. (Hospital Clínico San Carlos (Madrid)) ;
Avial, I.R. (Hospital Clínico San Carlos (Madrid)) ;
Rivilla, A.P. Hospital Universitario 12 de Octubre (Madrid) ;
Parra, P. (Hospital Universitario 12 de Octubre (Madrid)) ;
Fernández-Alonso, M. (Clínica Universitaria de Navarra (Pamplona)) ;
Treviño, A. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Requena, S. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Gutiérrez, L.B. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Mons, V.C. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
De Mendoza, C. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Barreiro, P. (Hospital Universitario La Paz (Madrid)) ;
Corral, O. (UNIR Health Sciences School & Medical Centre (Madrid)) ;
Gomez-Gallego, Felix ;
Universitat Autònoma de Barcelona
HTLV-1 infection is a neglected disease, despite infecting 10-15 million people worldwide and severe illnesses develop in 10% of carriers lifelong. Acknowledging a greater risk for developing HTLV-1 associated illnesses due to immunosuppression, screening is being widely considered in the transplantation setting. [...]
2019 - 10.1186/s12879-019-4346-z
BMC Infectious diseases, Vol. 19 Núm. 1 (september 2019) , p. 706
|
|
|
3.
|
|
7 p, 442.8 KB |
Treatment decision-making in chronic lymphocytic leukaemia : Key factors for healthcare professionals. PRELIC study
/
Boque, Concepcion (Institut Català d'Oncologia) ;
Abad, María Reyes (Hospital Universitario Miguel Servet (Saragossa)) ;
Agustin Ferrandez, Maria Jose (Hospital Universitario Miguel Servet (Saragossa)) ;
García-Goñi, Manuel (Universidad Complutense de Madrid) ;
Moreno, Carolina M. (Institut d'Investigació Biomèdica Sant Pau) ;
Gabás-Rivera, Clara (Outcomes 10) ;
Granados, Enrique (Gilead Sciences) ;
Castro-Gómez, Antonio (Gilead Sciences) ;
Pardo, Carlos (Gilead Sciences) ;
Lizán, Luis (Universitat Jaume I)
To explore the preferences of Spanish healthcare professionals (haematologists and hospital pharmacists) for the treatment selection of active Chronic Lymphocytic Leukaemia (CLL) patients at first relapse, condition that mainly afflicts older adults. [...]
2020 - 10.1016/j.jgo.2019.03.010
Journal of Geriatric Oncology, Vol. 11 Núm. 1 (january 2020) , p. 24-30
|
|
|
4.
|
|
7 p, 267.3 KB |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations : a pooled analysis from four clinical trials
/
Allan, John N. (Weill Cornell Medicine) ;
Shanafelt, Tait (Stanford University Medical Center) ;
Wiestner, Adrian (National Heart, Lung, and Blood Institute) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
O'Brien, Susan M. (University of California Irvine) ;
Li, Jianling (Pharmacyclics LLC) ;
Krigsfeld, Gabriel (Pharmacyclics LLC) ;
Dean, James P. (Pharmacyclics LLC) ;
Ahn, Inhye E. (National Heart, Lung, and Blood Institute) ;
Universitat Autònoma de Barcelona
TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy in patients with chronic lymphocytic leukaemia (CLL). We evaluated long-term efficacy and safety of first-line ibrutinib-based therapy in patients with CLL bearing TP53 aberrations in a pooled analysis across four studies: PCYC-1122e, RESONATE-2 (PCYC-1115/16), iLLUMINATE (PCYC-1130) and ECOG-ACRIN E1912. [...]
2021 - 10.1111/bjh.17984
British Journal of Haematology, Vol. 196 (december 2021) , p. 947-953
|
|
|
5.
|
|
9 p, 1.7 MB |
Survival improvement of patients with FLT3 mutated acute myeloid leukemia : results from a prospective 9 years cohort
/
Oñate, Guadalupe (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Pratcorona, Marta (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Artigas-Baleri, Alícia (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Bataller, Alex (Hospital Clínic i Provincial de Barcelona) ;
Tormo, Mar (Instituto de Investigación Sanitaria (València)) ;
Arnan, Montserrat (Institut d'Investigació Biomèdica de Bellvitge) ;
Vives Polo, Susana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Coll, Rosa (Institut Català d'Oncologia) ;
Salamero, Olga (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Sampol, Antonia (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Garcia, Antoni (Hospital Arnau de Vilanova (València)) ;
Cervera, Marta (Institut Catala d'Oncologia) ;
Garcia-Avila, Sara (Hospital del Mar (Barcelona, Catalunya)) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Ortín, Xavier (Hospital de Tortosa Verge de la Cinta) ;
Nomdedeu, Josep (Institut d'Investigació Biomèdica Sant Pau) ;
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Midostaurin added to intensive chemotherapy is the standard of care for acute myeloid leukemia (AML) with FLT3 mutations (FLT3 mut). We analyzed the impact of midostaurin in 227 FLT3 mut-AML patients included in the AML-12 prospective trial for fit patients ≤70 years (#NCT04687098). [...]
2023 - 10.1038/s41408-023-00839-1
Blood Cancer Journal, Vol. 13 (may 2023)
|
|
|
6.
|
|
9 p, 906.5 KB |
Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice : results from the NEUF study
/
Boissel, Nicolas (Saint-Louis Hospital. Division of Hematology, EA3518 Saint-Louis Institute for Research) ;
Chiaretti, Sabina ("Sapienza" University. Hematology Department of Translational and Precision Medicine) ;
Papayannidis, Cristina (Institute of Hematology "Seràgnoli". IRCCS, Azienda Ospedaliero Universitaria di Bologna) ;
Ribera, Jose-Maria (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Bassan, Renato (Complex Operative Unit of Hematology, dell'Angelo Hospital and Santissimi Giovanni and Paolo Hospital, Mestre and Venice, Venezia-Mestre, Italy) ;
Sokolov, Andrey N. (National Research Center for Hematology, Moscow) ;
Alam, Naufil (Amgen Ltd, Uxbridge, United Kingdom) ;
Brescianini, Alessandra (Amgen (Europe) GmbH, Rotkreuz, Switzerland) ;
Pezzani, Isabella (Amgen (Europe) GmbH, Rotkreuz, Switzerland) ;
Kreuzbauer, Georg (Amgen (Europe) GmbH, Rotkreuz, Switzerland) ;
Zugmaier, Gerhard (Amgen Research (Munich) GmbH, Munich, Germany) ;
Foà, Robin ("Sapienza" University. Hematology Department of Translational and Precision Medicine) ;
Rambaldi, Alessandro (University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII. Department of Oncology and Haematology)
This retrospective observational study (NEUF) included adult patients with B-cell acute lymphoblastic leukemia (B-cell ALL) who had received blinatumomab for the treatment of minimal residual disease-positive (MRD+) or relapsed/refractory (R/R) B-cell ALL via an expanded access program (EAP). [...]
2023 - 10.1038/s41408-022-00766-7
Blood Cancer Journal, Vol. 13 (january 2023)
|
|
|
7.
|
|
14 p, 2.9 MB |
GATA2 deficiency and MDS/AML : Experimental strategies for disease modelling and future therapeutic prospects
/
Kotmayer, Lili (Semmelweis University) ;
Romero-Moya, Damià (Institut d'Investigació Biomèdica de Bellvitge) ;
Marin-Béjar, Oskar (Institut d'Investigació Biomèdica de Bellvitge) ;
Kozyra, Emilia (University of Freiburg) ;
Català, Albert (Hospital Sant Joan de Deu) ;
Bigas Salvans, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Wlodarski, Marcin W. (St. Jude Children's Research Hospital (Memphis, Estats Units d'Amèrica)) ;
Bödör, Csaba (Semmelweis University) ;
Giorgetti, Alessandra (Universitat de Barcelona. Departament de Patologia i Terapèutica Experimental)
The importance of predisposition to leukaemia in clinical practice is being increasingly recognized. This is emphasized by the establishment of a novel WHO disease category in 2016 called "myeloid neoplasms with germline predisposition". [...]
2022 - 10.1111/bjh.18330
British Journal of Haematology, Vol. 199 Núm. 4 (november 2022) , p. 482-495
|
|
|
8.
|
|
|
9.
|
|
15 p, 2.9 MB |
Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with cd-33 positive acute myeloid leukaemia in spain
/
Mareque, M. (Pharmacoeconomics & Outcomes Research Iberia (PORIB)) ;
Montesinos, P. (Hospital Universitari i Politècnic La Fe (València)) ;
Font, P. (Hospital General Universitario Gregorio Marañón) ;
Guinea, J.M. (Organización Sanitaria Integrada Araba) ;
De La Fuente, Adolfo (Hospital MD Anderson) ;
Soto, J. (Pfizer) ;
Oyagüez, I. (Pharmacoeconomics & Outcomes Research Iberia (PORIB)) ;
Brockbank, J. (RTI Health Solutions) ;
Iglesias, Tomás (Pfizer) ;
Llinares, J. (Pfizer) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau)
Objective: To assess the incremental cost-utility ratio (ICUR) of gemtuzumab ozogamicin (GO) + standard of care (SOC) vs SOC alone for treatment of patients with de novo AML from a Spanish Health Service perspective. [...]
2021 - 10.2147/CEOR.S302097
ClinicoEconomics and outcomes research, Vol. 13 (2021) , p. 263-277
|
|
|
10.
|
|
16 p, 2.4 MB |
TYK2 Variants in B-Acute Lymphoblastic Leukaemia
/
Turrubiartes-Martínez, Edgar (Instituto de Investigación Hospital Universitario de la Princesa) ;
Bodega-Mayor, Irene (Instituto de Investigación Hospital Universitario de la Princesa) ;
Delgado-Wicke, Pablo (Instituto de Investigación Hospital Universitario de la Princesa) ;
Molina-Jiménez, Francisca (Instituto de Investigación Hospital Universitario de la Princesa) ;
Casique-Aguirre, Diana (Latin University of Mexico) ;
González-Andrade, Martín (Universidad Nacional Autónoma de México) ;
Rapado, Inmaculada (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Camós, Mireia (University Hospital Sant Joan de Déu) ;
Díaz de Heredia, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Barragán, Eva (Hospital Universitari i Politècnic La Fe (València)) ;
Ramírez, Manuel (Hospital Infantil Universitario Niño Jesús (Madrid)) ;
Aguado, Beatriz (Instituto de Investigación Hospital Universitario de la Princesa) ;
Figuera, Ángela (Instituto de Investigación Hospital Universitario de la Princesa) ;
Martínez-López, Joaquín (Complutense University of Madrid) ;
Fernández-Ruiz, Elena (Universidad Autónoma de Madrid) ;
Universitat Autònoma de Barcelona
B-cell precursor acute lymphoblastic leukaemia (B-ALL) is a malignancy of lymphoid progenitor cells with altered genes including the Janus kinase (JAK) gene family. Among them, tyrosine kinase 2 (TYK2) is involved in signal transduction of cytokines such as interferon (IFN) α/β through IFN−α/β receptor alpha chain (IFNAR1). [...]
2020 - 10.3390/genes11121434
Genes, Vol. 11 (november 2020)
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
